C
Cleave Therapeutics
Developing Novel Protein Degradation Inhibitors for the Treatment of Cancer
About Cleave Therapeutics
Cleave Biosciences, which later became Cleave Therapeutics, was a clinical-stage biopharmaceutical company established in 2011 to develop novel therapies for cancer and neurodegenerative diseases. The company was founded by a team of scientists including Raymond Deshaies, Ph.D., Seth Cohen, Ph.D., and Francesco Parlati, Ph.D., with initial leadership from CEO Laura Shawver, Ph.D. Dr. Deshaies, a world-renowned expert in protein degradation pathways, had previously co-founded Proteolix, the company behind the successful oncology drug carfilzomib. Dr. Shawver, a seasoned biotech executive and cancer survivor herself, brought over two decades of experience in developing small molecule drugs for cancer, which shaped the company's patient-centric approach.
The company's core focus was on inhibiting the valosin-containing protein (VCP)/p97, a critical enzyme that regulates protein homeostasis—a process that cancer cells become overly dependent on for survival. By targeting VCP/p97, Cleave aimed to disrupt multiple cellular stress pathways, pushing cancer cells toward apoptosis. The business model centered on the discovery and clinical development of small-molecule inhibitors targeting this pathway, with the goal of creating first-in-class drugs for patients with difficult-to-treat cancers. Revenue generation was planned through licensing agreements and the eventual commercialization of its drug candidates. A significant milestone was a 2021 licensing agreement with CASI Pharmaceuticals to develop and commercialize its lead candidate in Greater China, which involved a $5.5 million upfront payment and potential for $74 million in milestones plus royalties.
Cleave's lead product candidate was CB-5339, a second-generation, oral, selective inhibitor of VCP/p97. This compound was designed to overcome the limitations of earlier inhibitors, offering better target selectivity and exposure. The company advanced CB-5339 into a Phase 1 clinical trial for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The trial, which began in 2020, showed the drug was well-tolerated and demonstrated signs of clinical activity. In a major strategic development in July 2023, Cleave's assets were acquired by two separate entities: CASI Pharmaceuticals acquired the global rights to the clinical asset CB-5339, while Eikon Therapeutics acquired the company's preclinical assets and chemical library to explore other novel targets.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 60.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Oncology, Spinout, Alternative Protein, Macro-Nutrients, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B, B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Aug 2019 | $12M | $48M | Celgene · U.S. Venture Partners · Bristol-Myers Squibb · OrbiMed | — |
| SERIES BOther financing | Aug 2016 | $37M | $148M | 5AM Ventures · Clarus Ventures · Osage University Partners · NEA | — |
Growth signals
Latest recorded traffic for Cleave Therapeutics is 2.6K monthly website visits, up 62.5% over the last three months. Cleave Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cleave Therapeutics in the San Francisco ecosystem
The Cleave Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Series B and later2 investors entered at this stage
U.S. Venture Partners
Bristol-Myers Squibb
Other known investors1 additional known investor
Rush University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cleave Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cleave Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.


















